ESTRO 2020 Abstract Book

S598 ESTRO 2020

Purpose or Objective Endometrial cancer is surgically staged, and while surgery is the primary treatment modality, the identification of disease extent - in particular extrauterine spread - prior to surgery is important to optimize the treatment decision making. Aim of this study was to define the role of 18- Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (18F-FDG-PET/CT) in the adjuvant treatment of high-risk endometrial cancer (HR-EC) defined based on FIGO stage, histotype, grading and performed lymphadenectomy. Material and Methods HR-EC patients referred to our radiation therapy centre between 2008 and 2018 that had been treated by surgery and had performed a postoperative 18F-FDG- PET/CT exam were included in the study. The primary endpoint was to investigate the role of 18F-FDG-PET/CT in changing indication and type of HR-EC adjuvant treatment. Results Fifty-eight patients (median age 67.5 years, range 48-86) entered the analysis. Overall, 34 patients (58.6%) showed negative 18F-FDG-PET/CT imaging, 6 patients (10.4%) had doubtful uptakes and 18 patients (31%) had an FDG intense uptake in different sites: pelvic disease, pelvic or paraaortic lymph nodes, metastases or an association of those possibilities. Patients without or with doubtful uptake underwent radiotherapy according to international guidelines, while among patients with pathologic uptake, 6 did not receive irradiation treatment: 4 patients due to distant metastasis that were treated with chemotherapy, one due to long lasting surgical complications and one for clinical decisions. On the contrary, 12 patients underwent to modified external beam radiotherapy based on 18F- FDG-PET/CT: 10 patients received a sequential or concomitant radiotherapy boost on the PET positive areas, one patient underwent to a vaginal cuff brachytherapy boost and one patient had an enlargement of the treated volume. Conclusion According to international guidelines, the role of 18F-FDG- PET/CT in the adjuvant setting of endometrial cancer is not yet clearly defined. In the present series we reported 31 % of cases in which the planned adjuvant treatment changed based on 18F-FDG-PET/CT findings. PO-1135 Place of radiotherapy as part of multimodal management of cervical glassy cell carcinoma J. Boustani 1 , S. Achkar 2 , A. Bartaut 3 , C. Genestie 4 , S. Gouy 5 , M. Kissel 2 , P. Pautier 6 , P. Morice 5 , C. Haie-Meder 2 , C. Chargari 2 1 Centre Georges François Leclerc, Radiation Oncology, Dijon, France ; 2 Gustave Roussy, Brachytherapy, Villejuif, France ; 3 Centre Georges François Leclerc, Biostatistics, Dijon, France ; 4 Gustave Roussy, Anotomopathology, Villejuif, France ; 5 Gustave Roussy, Gynecologic surgery, Villejuif, France ; 6 Gustave Roussy, Medical Oncology, Villejuif, France Purpose or Objective Objective: Glassy cell carcinoma (GCC) of the uterine cervix is a rare entity, accounting for 1-2% of all cervical carcinoma. This study aims at describing the clinical characteristics and outcomes of cervical GCC patients treated in a comprehensive cancer center. Material and Methods Material and Methods: We retrospectively reported patients and tumors characteristics, therapeutic management, overall survival (OS), progression-free progression (PFS), relapse rates, and toxicities. Results Results: Between 1994 and 2014, 55 patients were treated with curative intent. The median age at diagnosis was 41 years (range, 20-68). Among 22 patients with early stage tumors (IA2-IB1-IIA1), 17 had preoperative brachytherapy,

4.5%, G2 2% and rectal chronic toxicity G1 4.5%, G2 2%, G3 4.5% (2 patients). We have not observed G3 toxicity intestinal or bladder. Conclusion Our results show that HDR-BT MRI based IGABT allows doses to be administered >90 Gy to HDR-CTV getting a good LC whit acceptable toxicity. We need to get better the overall treatment time. PO-1133 Concurrent chemoradiotherapy with or without brachytherapy; a retrospective clinical study B. Khadidja 1 , Z. Benyoucef 1 , S. Sebti 1 , L. Hamzi 1 , F. Boulekhsaim 2 , H. Boukabous 2 , S. Khalfa 2 , M. Zarroug 2 , Z. Griballah 2 , S. Toukal 2 , S. Khoudri 3 1 CLCC Mokhtari Abdelghani- Faculty of Medicine- University Farhat Abes Setif 1, Radiation oncologist, Setif, Algeria ; 2 CLCC Mokhtari Abdelghani Setif, Radiation oncologist, Setif, Algeria ; 3 CLCC Mokhtari Abdelghani- University Farhat Abes Setif 1, Radiation oncologist, Setif, Algeria Purpose or Objective External beam radiotherapy (EBRT) combined at brachytherapy (ICBT) are well established as the standard radical radiotherapy (RT) for cervical cancer. However, in our department brachytherapy is not available, patients who could not move to another anti-cancer center which is about 1000 km, received EBRT alone with three- dimensional conformal radiotherapy (3DCRT). The purpose of this study is to evaluate the results of EBRT with or without ICBT for patients with cervical cancer. Material and Methods 95 patients with cervical carcinoma (stage: IIb to IV) were treated with concurrent chemoradiation (3DCRT) with or without brachytherapy, between 2014 and 2018. there were 88 squamous cell carcinoma, and 7 adenocarcinomas. The median patient age was 60 years, ranging from 37 to 85 years. 63 IIb, 15III (8IIIA, 7IIIB) and 17 IV. Only 14 patients were benefited to ICBT. A dose of 66 Gy was delivered in 36 cases, 39 patients received 60Gy, by conventional fractionation without intracavitary brachytherapy. Only 14 patients received EBRT followed by intra cavitary brachytherapy. Results The 3-year overall survival (OAS) and local control (LC) rates were 65.3% and 75.7% respectively. The 3-year overall survival (OAS) was 71.4% for the EBRT with ICBT group, 64.2% for the External Beam Boost without ICBT group (P=0.031) . Conclusion Pelvic EBRT in combination with vaginal brachytherapy, in cervical cancer patients had a reduced risk of locoregional recurrence without increased side effects compared with patients treated with pelvic EBRT and External Beam Boost without vaginal brachytherapy. PO-1134 18F-FDG-PET/CT role in the adjuvant setting of endometrial cancer M. Ferioli 1 , V. Panni 1 , A. Galuppi 2 , A. Zamagni 1 , M. Buwenge 1 , G. Macchia 3 , F. Deodato 3 , A. Re 3 , M. Boccardi 3 , S. Cilla 4 , S. Fanti 5 , A.G. Morganti 1 , S. Cammelli 1 1 Sant'Orsola-Malpighi Hospital- University of Bologna- Bologna- Italy, Radiation Oncology Unit- Department of Experimental- Diagnostic and Specialty Medicine DIMES, Bologna, Italy ; 2 Sant'Orsola-Malpighi Hospital- University of Bologna- Bologna- Italy, Radiation Oncology Unit, Bologna, Italy ; 3 Giovanni Paolo II Foundation- Campobasso- Italy, Radiotherapy Unit- General Oncology Unit - Università Cattolica del Sacro Cuore, Campobasso, Italy ; 4 Giovanni Paolo II Foundation- Campobasso- Italy, Medical Physics Unit- Università Cattolica del Sacro Cuore, Campobasso, Italy ; 5 Sant'Orsola-Malpighi Hospital- University of Bologna- Bologna- Italy, Nuclear Medicine Unit- Department of Experimental- Diagnostic and Specialty Medicine DIMES, Bologna, Italy